



---

September 17, 2020

**Via EDGAR Transmission**

United States Securities and Exchange Commission  
Division of Corporation Finance  
100 F Street, N.E.  
Washington, D.C. 20549  
Attn: Chris Edwards

**Re: Kiniksa Pharmaceuticals, Ltd.  
Registration Statement on Form S-3  
Filed September 8, 2020  
Registration No. 333-248656**

Dear Mr. Edwards:

In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request the acceleration of the effective date of the above-referenced Registration Statement so that it will become effective on September 21, 2020 at 4:00 p.m., Eastern Time, or as soon thereafter as practicable, or at such later time as Kiniksa Pharmaceuticals, Ltd. (the "Company") or its counsel may request via telephone call to the staff. Please contact Nathan Ajiashvili of Latham & Watkins LLP, counsel to the Company, at (212) 906-2916, or in his absence, Jennifer Yoon at (617) 880-4540, to provide notice of effectiveness, or if you have any other questions or concerns regarding this matter.

Clarendon House | 2 Church Street Hamilton | HM11 Bermuda  
Telephone: 808.451.3453  
[www.kiniksa.com](http://www.kiniksa.com)

---



---

Very truly yours,

**KINIKSA PHARMACEUTICALS, LTD.**

/s/ Thomas Beetham

Thomas Beetham

Executive Vice President, Chief Legal Officer

cc: Johan V. Brigham, Latham & Watkins LLP  
Nathan Ajiashvili, Latham & Watkins LLP

Clarendon House | 2 Church Street Hamilton | HM11 Bermuda  
Telephone: 808.451.3453  
[www.kiniksa.com](http://www.kiniksa.com)

---